About: Oncolytic Virus With Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Oncolytic Virus With Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Oncolytic Virus With Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers
Creator	Zhou, Yumei Roberts, Stephen Arora, James Arora, Mansi Baker, Alexander Baker, Dan Barro, Michael Barro, Oumar Bm, Nagalo Bogenberger, James Bogenberger, Oumar Bolni, Marius Borad, Borad, Mitesh Breton, Ayala Breton, Borad Breton, Yumei Ca, Breton Camilo, Nagalo Duda, Dan Duda, Lewis Jenks, Alexander Jenks, Nathan Jm, Bogenberger Kah, Stephen Marius, Bolni Nagalo, Ayala Peng, Mitesh Peng, Whye Roberts, Lewis Russell, Whye Steele, Barro Steele, Messrs Steele, Michael Steele, Nathan Zhou, Mansi
Source	Elsevier; Medline; PMC
abstract	Abstract Recombinant vesicular stomatitis virus (VSV)-fusion and hemagglutinin (FH) was developed by substituting the promiscuous VSV-G glycoprotein (G) gene in the backbone of VSV with genes encoding for the measles virus envelope proteins F and H. Hybrid VSV-FH exhibited a multifaceted mechanism of cancer-cell killing, and improved neurotolerability over parental VSV in preclinical studies. In this study, we evaluated VSV-FH in vitro and in vivo in models of hepatobiliary and pancreatic cancers. Our results indicate that high intrahepatic doses of VSV-FH did not result in any significant toxicity and were well tolerated by transgenic mice expressing the measles virus receptor CD46. Furthermore, single intratumoral treatments with VSV-FH yielded improved survival and complete tumor regressions in a proportion of mice in the Hep3B hepatocellular carcinoma model, but not in mice xenografted with BxPC3 pancreatic cancer cells. Our preliminary findings indicate that VSV-FH can induce potent oncolysis in hepatocellular and pancreatic cancer cell lines with concordant results in vivo in hepatocellular cancer and discordant in pancreatic cancer, without the VSV-mediated toxic effects previously observed in laboratory animals. Further study of VSV-FH as an oncolytic virotherapy is warranted in hepatocellular carcinoma and pancreatic cancer, to understand broader applicability and mechanisms of sensitivity and resistance.
has issue date	2020-08-19(xsd:dateTime)
bibo:doi	10.1016/j.omto.2020.08.007
bibo:pmid	32839735
has license	els-covid
sha1sum (hex)	93d4431bafc8d70488255f6e45332e4a4eb28027
schema:url	https://doi.org/10.1016/j.omto.2020.08.007
resource representing a document's title	Oncolytic Virus With Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers
has PubMed Central identifier	PMC7437509
has PubMed identifier	32839735
schema:publication	Mol Ther Oncolytics
resource representing a document's body	covid:93d4431bafc8d70488255f6e45332e4a4eb28027#body_text
is schema:about of	named entity 'Please' named entity 'Pancreatic' named entity 'Pancreatic' named entity 'definitive' named entity 'legal' named entity 'This' named entity 'article' named entity 'Virus' named entity 'Oncolytic Virus' named entity 'Cancers' named entity 'Virus' named entity 'typesetting' named entity 'metadata' named entity 'Hepatobiliary' named entity 'Measles Virus' named entity 'content' named entity 'causality' named entity 'CD46' named entity 'VSV' named entity 'oncolytic' named entity 'transgenic mouse model' named entity 'murine' named entity 'CD46' named entity 'cytotoxic effects' named entity 'blood-brain barrier' named entity 'laboratory rodents' named entity 'neurotoxic' named entity 'green fluorescent protein' named entity 'wild-type' named entity 'CD46' named entity 'oncolytic virus' named entity 'adenoviruses' named entity 'VSV' named entity 'liver damage' named entity 'CD46' named entity 'statistically significant' named entity 'clinical trial' named entity 'Mayo Clinic' named entity 'significant difference' named entity 'cell lines' named entity '45 days' named entity 'body weight' named entity 'VSV' named entity 'tropism' named entity 'animal models' named entity 'liver toxicity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software